Comparative Pharmacology
Head-to-head clinical analysis: ALLOPURINOL versus ULORIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLOPURINOL versus ULORIC.
ALLOPURINOL vs ULORIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations. It also inhibits de novo purine synthesis through feedback inhibition.
ULORIC (febuxostat) is a xanthine oxidase inhibitor that reduces serum uric acid levels by inhibiting the enzyme xanthine oxidase, which catalyzes the conversion of hypoxanthine to xanthine and xanthine to uric acid.
100-600 mg orally once daily; initial 100 mg/day with weekly increases of 100 mg/day; maximum 800 mg/day.
40 mg orally once daily; may increase to 80 mg once daily if serum uric acid not at target after 2 weeks.
None Documented
None Documented
Clinical Note
moderateAllopurinol + Hydrochlorothiazide
"The risk of a hypersensitivity reaction to Hydrochlorothiazide is increased when it is combined with Allopurinol."
Clinical Note
moderateAllopurinol + Bendroflumethiazide
"The risk of a hypersensitivity reaction to Bendroflumethiazide is increased when it is combined with Allopurinol."
Clinical Note
moderateAllopurinol + Methyclothiazide
"The risk of a hypersensitivity reaction to Methyclothiazide is increased when it is combined with Allopurinol."
Clinical Note
moderateAllopurinol: 1–2 hours; oxypurinol: 18–30 hours (prolonged in renal impairment).
Terminal elimination half-life is approximately 5-8 hours. This short half-life supports once-daily dosing for maintenance of therapeutic urate-lowering effect.
Renal: ~76% as unchanged drug and metabolites; oxypurinol (active metabolite) is primarily excreted renally. Biliary/fecal: minor, <5%.
Renal excretion of unchanged drug accounts for approximately 40-45% of the dose. Biliary/fecal excretion eliminates about 50-55% of the dose, primarily as oxidative metabolites.
Category C
Category C
Xanthine Oxidase Inhibitor
Xanthine Oxidase Inhibitor
Allopurinol + Hydroflumethiazide
"The risk of a hypersensitivity reaction to Hydroflumethiazide is increased when it is combined with Allopurinol."